Cohort baseline demographics
| . | 3-4 cycles n = 299∗ . | 5-6 cycles n = 633∗ . | P value . |
|---|---|---|---|
| Survival status at data cut-off | |||
| Alive | 216 (72%) | 499 (79%) | |
| Dead | 83 (28%) | 134 (21%) | |
| Age, y, at treatment start, mean (range) | 76.2 (66.1-96.0) | 75.0 (66.1-91.5) | <.01 |
| Sex | .70 | ||
| Male | 149 (50%) | 307 (48%) | |
| Female | 150 (50%) | 326 (52%) | |
| Race | .53 | ||
| White | 282 (95%) | 586 (94%) | |
| Non-White | 15 (5%) | 38 (6%) | |
| NCI comorbidity index | 2.0 (2.1) | 1.7 (1.8) | .05 |
| Ann Arbor stage | .82 | ||
| I-II | 103 (37%) | 205 (34%) | |
| III-IV | 179 (63%) | 391 (66%) | |
| Missing | 17 | 37 | |
| Histologic grade | .07 | ||
| Grade 1-2 | 169 (57%) | 395 (62%) | |
| Grade 3 | 44 (15%) | 70 (11%) | |
| NOS | 86 (29%) | 168 (27%) | |
| History of other cancer | 56 (19%) | 118 (19%) | .97 |
| Second primary malignancy† | 39 (13%) | 82 (13%) | .97 |
| Prior use of rituximab | 84 (28%) | 139 (22%) | .04 |
| Concurrent rituximab‡ | >280 (>94%) | 622 (98%) | .12 |
| Subsequent use of rituximab | 168 (56%) | 393 (62%) | .09 |
| Nonmetropolitan county | 68 (23%) | 97 (15%) | <.01 |
| Region | .01 | ||
| Midwest | 49 (16%) | 71 (11%) | |
| Northeast | 42 (14%) | 107 (17%) | |
| South | 84 (28%) | 139 (22%) | |
| West | 123 (41%) | 309 (49%) | |
| Time from diagnosis to first bendamustine treatment, mo | 18.2 (32.8) | 11.7 (23.4) | <.01 |
| Zip code median income (SD) | $43 944 ($20 789) | $49 205 ($23 999) | <.01 |
| Zip code median proportion with high school only education | 28% | 26% | <.01 |
| Zip code median proportion with college education of ≥4 y | 22% | 25% | .03 |
| . | 3-4 cycles n = 299∗ . | 5-6 cycles n = 633∗ . | P value . |
|---|---|---|---|
| Survival status at data cut-off | |||
| Alive | 216 (72%) | 499 (79%) | |
| Dead | 83 (28%) | 134 (21%) | |
| Age, y, at treatment start, mean (range) | 76.2 (66.1-96.0) | 75.0 (66.1-91.5) | <.01 |
| Sex | .70 | ||
| Male | 149 (50%) | 307 (48%) | |
| Female | 150 (50%) | 326 (52%) | |
| Race | .53 | ||
| White | 282 (95%) | 586 (94%) | |
| Non-White | 15 (5%) | 38 (6%) | |
| NCI comorbidity index | 2.0 (2.1) | 1.7 (1.8) | .05 |
| Ann Arbor stage | .82 | ||
| I-II | 103 (37%) | 205 (34%) | |
| III-IV | 179 (63%) | 391 (66%) | |
| Missing | 17 | 37 | |
| Histologic grade | .07 | ||
| Grade 1-2 | 169 (57%) | 395 (62%) | |
| Grade 3 | 44 (15%) | 70 (11%) | |
| NOS | 86 (29%) | 168 (27%) | |
| History of other cancer | 56 (19%) | 118 (19%) | .97 |
| Second primary malignancy† | 39 (13%) | 82 (13%) | .97 |
| Prior use of rituximab | 84 (28%) | 139 (22%) | .04 |
| Concurrent rituximab‡ | >280 (>94%) | 622 (98%) | .12 |
| Subsequent use of rituximab | 168 (56%) | 393 (62%) | .09 |
| Nonmetropolitan county | 68 (23%) | 97 (15%) | <.01 |
| Region | .01 | ||
| Midwest | 49 (16%) | 71 (11%) | |
| Northeast | 42 (14%) | 107 (17%) | |
| South | 84 (28%) | 139 (22%) | |
| West | 123 (41%) | 309 (49%) | |
| Time from diagnosis to first bendamustine treatment, mo | 18.2 (32.8) | 11.7 (23.4) | <.01 |
| Zip code median income (SD) | $43 944 ($20 789) | $49 205 ($23 999) | <.01 |
| Zip code median proportion with high school only education | 28% | 26% | <.01 |
| Zip code median proportion with college education of ≥4 y | 22% | 25% | .03 |